NITE - Nightstar Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
25.31
+0.11 (+0.44%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close25.20
Open25.20
Bid0.00 x 1000
Ask0.00 x 900
Day's Range25.15 - 25.50
52 Week Range9.59 - 29.55
Volume1,621,440
Avg. Volume395,343
Market Cap848.738M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.28
Trade prices are not sourced from all markets
  • Motley Fool14 days ago

    Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next?

    Roche and Biogen are spending big bucks on gene therapy biotech stocks.

  • ACCESSWIRE14 days ago

    Rare Disease Therapies Draw Big Biopharma's Interest

    HENDERSON, NV / ACCESSWIRE / March 8, 2019 / The past few weeks have been busy with big bio taking over smaller biotechs developing novel therapies. Roche (RHHBY) said it would spend $4.8 billion in a ...

  • Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More
    Zacks16 days ago

    Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More

    Key highlights of the past week are merger agreements plus regulatory and pipeline developments.

  • Biogen to Acquire Gene-Therapy Company Nightstar for $800M
    Zacks17 days ago

    Biogen to Acquire Gene-Therapy Company Nightstar for $800M

    Biogen (BIIB) to acquire gene-therapy company, Nightstar Therapeutics to accelerate entry into ophthalmology space.

  • How Much Does Biogen Gain From Its $800 Million Gene Therapy Buyout?
    Investor's Business Daily17 days ago

    How Much Does Biogen Gain From Its $800 Million Gene Therapy Buyout?

    Biogen's pending acquisition of gene therapy player Nightstar Therapeutics only offers a "modest pipeline boost," an analyst said Tuesday. Nightstar is working on therapies for eye diseases.

  • Benzinga17 days ago

    Analysts Laud Biogen's M&A Strategy Following Deal to Buy Gene Therapy Company Nightstar

    Biogen Inc (NASDAQ: BIIB ) announced Monday a deal to buy gene therapy biotech Nightstar Therapeutics PLC (NASDAQ: NITE ) for $800 million. The Analysts Baird analyst Brian Skorney maintained a Neutral ...

  • Company News For Mar 5, 2019
    Zacks17 days ago

    Company News For Mar 5, 2019

    Companies in the news are; PLCE, BIIB, NITE, ASND and TAK

  • Stock Market Today: Biogen Buys Gene Therapy Company Nightstar Therapeutics
    Motley Fool17 days ago

    Stock Market Today: Biogen Buys Gene Therapy Company Nightstar Therapeutics

    Elsewhere, Village Farms jumps into the U.S. hemp market.

  • Associated Press18 days ago

    Nightstar Therapeutics soars while Children's Place tumbles

    Stocks that moved substantially or traded heavily on Monday: Children's Place Inc., down $9.78 to $84.82 The children's clothing retailer reported weak fourth-quarter results and issued a weak forecast. ...

  • Biogen Shores Up Gene Therapy Assets With $800 Million Takeover
    Investor's Business Daily18 days ago

    Biogen Shores Up Gene Therapy Assets With $800 Million Takeover

    Nightstar Therapeutics soared early Monday after Biogen pledged to spend $800 million to buy the gene therapy firm. The smaller biotech is working on gene therapies in rare eye diseases.

  • NITE, BIIB: Nightstar Therapeutics Stock Soars on Biogen Buy
    InvestorPlace18 days ago

    NITE, BIIB: Nightstar Therapeutics Stock Soars on Biogen Buy

    Nightstar Therapeutics stock was soaring on Monday following news that Biogen (NASDAQ:BIIB) is acquiring it.Source: Biogen via YouTubeThe deal will have Biogen spending a total of $877 million to acquire Nightstar Therapeutics (NASDAQ:NITE). This will have the company paying $25.50 in cash for each share of Nightstar Therapeutics stock.The offer price of $25.50 per share for Nightstar Therapeutics stock represents a 70% premium to the stock's 30 trading day volume-weighted average price. It is also a 68% premium over the stock's closing price from Friday.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBiogen notes that all issued and to be issued shares of Nightstar Therapeutics stock will be acquired by Tungsten Bidco Limited. This is a newly-incorporated company and wholly-owned subsidiary of BIIB."I am proud of Nightstar's achievements, delivering two proof-of-concept programs and building a world class organisation," Chris Hollowood, Chairman of Nightstar Therapeutics, said in a statement. "We look forward to seeing the next chapter of Nightstar's journey under Biogen's ownership, as it works to achieve its ultimate ambition of delivering transformational treatments to patients."Biogen and Nightstar Therapeutics are expecting the acquisition deal to close during mid-2019. However, it will first have to get regulatory approval and complete other customary closing conditions. Among these is approval from holders of Nightstar Therapeutics stock for the deal. The acquisition does not need approval from shareholders of BIIB. * 7 Top-Rated Stocks to Buy for March Nightstar Therapeutics is getting its financial advice for the deal from Centerview Partners and Jefferies LLC. The company's legal advice concerning the matter is coming from Arps, Slate, Meagher & Flom LLP.Nite stock was up 66% and BIIB stock was down 2% as of noon Monday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Retail Stocks Ready to Break Out * 7 Strong Buy Stocks the Street Loves * 10 Best Stocks to Buy and Hold Forever As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post NITE, BIIB: Nightstar Therapeutics Stock Soars on Biogen Buy appeared first on InvestorPlace.

  • Biogen Buys Nightstar Therapeutics in $800 Million Deal
    GuruFocus.com18 days ago

    Biogen Buys Nightstar Therapeutics in $800 Million Deal

    Becoming the latest players in the health care space to consolidate, Biogen Inc. (BIIB) announced on Monday morning it is buying London-based gene therapy company Nightstar Therapeutics PLC (NITE) for $800 million. According to the terms of the all-cash deal, the Cambridge, Massachusetts-based biotech company will pay $25.50 per share of Nightstar, which represents a 68% premium to its closing price of $15.16 on Friday. Warning! GuruFocus has detected 5 Warning Sign with TSX:ATD.B. Click here to check it out.

  • Biogen Makes Gene Therapy Splash as Street Wonders What's Next
    Bloomberg18 days ago

    Biogen Makes Gene Therapy Splash as Street Wonders What's Next

    Analysts including Jefferies’s Michael Yee said Biogen still needs to do more to move the needle. Nightstar jumped 66 percent to $25.18, just shy of the $25.50-a-share offer. The acquisition comes just a week after Roche Holding AG made a $4.8 billion bid for Spark Therapeutics Inc. Nightstar’s pipeline includes a pair of late-stage treatment candidates for rare inherited retinal diseases.

  • Why Nightstar Therapeutics Stock Is Soaring Today
    Motley Fool18 days ago

    Why Nightstar Therapeutics Stock Is Soaring Today

    Biogen takes out Nightstar Therapeutics for its pipeline of novel gene therapies.

  • TheStreet.com18 days ago

    Nightstar Soars as Biogen to Buy Gene Therapy Company for $877 Million

    Nightstar shares were up 66% to $25.16 in trading Monday. Biogen's offer for Nighstar is $25.50 a share. Nightstar makes gene therapy treatments for choroideremia, a rare, inherated eye disease that leads to blindness.

  • Benzinga18 days ago

    Biogen Bets On Gene Therapy, Agrees To Acquire Nightstar For $800M

    Biogen Inc (NASDAQ: BIIB ) is the latest biotech company to jump onto the gene therapy bandwagon . What To Know Biogen, which focuses on developing therapies for neurological and neurodegenerative diseases, ...

  • MarketWatch18 days ago

    Nightstar Therapeutics' stock rockets on Biogen buyout deal valued at $877 million

    Shares of Nightstar Therapeutics PLC rocketed 67% to pace all premarket gainers in very active trade, after the gene therapy company agreed to be acquired by Biogen Inc. in a cash deal valued at about $877 million. Trading volume in Nightstar spiked to over 570,000 shares, compared with the full-day average of about 71,300 shares. Under terms of the deal, U.K.-based Nightstar shareholders will receive $25.50 for each Nightstar share they own, which represents a 68% premium to Friday's closing price of $15.16. The deal is expected to become effective by mid-year 2019. "This transaction accelerates treatment to patients through Nightstar's key retinal gene therapy programs that modify or halt progression of blindness," said Nightstar Chief Executive David Fellows. Nightstar shares have climbed 15.7% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has gained 5.0% and the S&P 500 has advanced 4.2%.

  • The Wall Street Journal18 days ago

    [$$] Biogen Buys Gene Therapy for Rare Eye Disease

    The all-cash deal, which values Nightstar at around $877 million, hands Biogen a gene therapy for choroideremia, a rare, inherited eye disease that leads to blindness. The treatment is undergoing late-stage clinical trials. Nightstar, which was founded in 2013 based on research at the University of Oxford, also has several earlier-stage gene therapies in its pipeline, all aimed at rare inherited eye disorders.

  • Reuters18 days ago

    Biogen to buy Nightstar Therapeutics in $800 mln cash deal

    Biogen Inc said on Monday it will buy Nightstar Therapeutics Plc for about $800 million in cash as the company looks to tap into a potentially lucrative gene therapy market. Biogen's offer of $25.50 per ...

  • GlobeNewswire18 days ago

    Nightstar Therapeutics plc reaches agreement to be acquired by Biogen

    Nightstar Therapeutics plc ("Nightstar") (NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases and Biogen Inc. ("Biogen") are pleased to announce that they have reached agreement on the terms of a recommended acquisition whereby the entire issued and to be issued share capital of Nightstar will be acquired by Tungsten Bidco Limited (a newly-incorporated company and wholly-owned subsidiary of Biogen Switzerland Holdings GmhH (“Bidder”)). It is intended that the Acquisition will be implemented by means of a U.K. Court-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006. Under the terms of the Acquisition, Nightstar Shareholders will be entitled to receive USD 25.50 in cash for each Nightstar Share.

  • Mizuho's 9 Best Biotech Stocks to Buy for 2019
    Kiplingerlast month

    Mizuho's 9 Best Biotech Stocks to Buy for 2019

    Biotech stocks are a staple among growth investors. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the risk is just as high. It's not unusual for these stocks to be cut in half or worse if drug-trial data disappoints or a drug application is rejected. Thus, proper due diligence is critical, and that includes tapping the experts for information about these often difficult-to-gauge stocks. Mizuho Securities has recently put out an analyst report highlighting its top biotechnology picks for 2019. And thanks to analyst ranking service TipRanks, we can see that the report's author, Managing Director Difei Yang, has a strong track record of stock recommendations. Yang is ranked in the top 250 out of more than 5,100 tracked analysts. Yang writes, "We favor innovative and ground-breaking therapies in 2019; emerging technologies such as gene therapy and cell therapy could command substantial premiums from large cap pharma/biotech if impressive results are shown in historically difficult-to-treat conditions." As Yang points out, pharma M&A; is off to a strong start in 2019 with a number of blockbuster deals. They include Bristol-Myers Squibb's (BMY) $74 billion acquisition of Celgene (CELG), and Eli Lilly's (LLY) $8 billion buyout of Loxo Oncology (LOXO). "In our view, the transactions underscore the persistent need by large pharma to fuel continued growth and replenish R&D; pipelines via M&A;," she writes. Here are Mizuho's top nine biotech stocks to buy right now. Many of them can stand on their own but look even better as potential buyout targets. ### SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)

  • Is Nightstar Therapeutics plc (NITE) Going to Burn These Hedge Funds?
    Insider Monkey3 months ago

    Is Nightstar Therapeutics plc (NITE) Going to Burn These Hedge Funds?

    During the first half of the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by about 4 percentage points as investors worried over the possible ramifications of rising interest rates. The hedge funds and institutional investors we track typically invest more in smaller-cap stocks than an average investor (i.e. […]

  • GlobeNewswire4 months ago

    Nightstar Announces Planned Initiation of Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP and Reports Third Quarter 2018 Financial Results

    Phase 2/3 Expansion Study to Include No-Sham Control Arm in Alignment with FDA Draft Guidance on Development of Gene Therapy Products for Retinal Disorders Preliminary Efficacy.